Inhibrx announces an Option & License Agreement with Celgene for Inhibrx Antibody Program

La Jolla, CA.– June 27, 2012 – Inhibrx LLC today announced a worldwide Option and License Agreement with Celgene for an Inhibrx Antibody Program. The target of this Antibody Program was not disclosed. “Inhibrx has developed an antibody with strong pre-clinical study results on a highly validated target with very promising therapeutic potential,” said Tom Daniel, M.D., President of Research and Early Development for Celgene Corporation. “We are pleased to have a company of Celgene’s caliber as the licensee of this program. On a global basis, Celgene has the science, clinical, regulatory and commercial expertise as well as the commitment to patients that continue to deliver disease-altering solutions to patients in need as quickly as possible,” stated Mark Lappe, CEO of Inhibrx. The total deal potential is in excess of $500M. This includes upfront, clinical and regulatory milestone payments. Additionally, Inhibrx is eligible to receive royalties on commercial sales. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit About Inhibrx Inhibrx is a biotherapeutic discovery and development company, with an extensive internally developed pipeline. Active programs are focused on cancer, inflammatory and metabolic diseases. Inhibrx’s programs are based on comprehensive target discovery and selection expertise coupled to the creative implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement and optimization. For more information, please visit CONTACT: Inhibrx LLC: Mark Lappe, 858-759-1499 Chief Executive Officer

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.